Axsome & Antecip v. Teva: DXM/Bupropion ER Patent Case Consolidated in 23 Days
Axsome Therapeutics and Antecip Bioventures II filed suit in New Jersey against Teva Pharmaceutical over three patents covering dextromethorphan hydrobromide and bupropion hydrochloride extended-release tablets. The case was administratively terminated and merged into a parallel lead action within just 23 days, consolidating all discovery and trial proceedings.
Parallel ANDA suits over DXM/bupropion ER tablets merged into a single New Jersey action
On September 30, 2024, Axsome Therapeutics, Inc. and Antecip Bioventures II LLC filed Civil Action No. 24-9535 in the District of New Jersey against Teva Pharmaceutical Industries, Ltd., asserting infringement of three U.S. patents — US11986444B2, US12036191B1, and US12042473B2 — covering dextromethorphan hydrobromide and bupropion hydrochloride extended-release tablets, the active combination behind Axsome’s branded product Auvelity.
The case closed within 23 days, not through litigation on the merits, but via a jointly requested consolidation order. Both parties agreed to merge 24-9535 with a closely related earlier action, Civil Action No. 24-6489, which had been filed on May 28, 2024, and amended on June 3, 2024. Going forward, all filings, discovery, case management, and trial in the consolidated actions will proceed exclusively under the 24-6489 docket.
The swift consolidation suggests the parties recognised significant factual and legal overlap between the two actions, consistent with standard ANDA multi-wave filing strategy where additional patents are listed in an Orange Book after the initial suit. What remains unresolved from the public record of this docket alone is the scope of Teva’s ANDA, the specific claims at issue, and the anticipated trial schedule — all of which will now be governed by the lead action.
Filing to Case Consolidated in 23 days
Case closed by consolidation order in 23 days — well below median ANDA district court resolution timelines
Case consolidated into lead action: what the order means for both parties
Consolidation under Rule 42 merges two related ANDA suits
When multiple patent infringement actions in the same district share common questions of fact or law, courts may consolidate them under Federal Rule of Civil Procedure 42(a). Here, both parties jointly requested the order. Civil Action No. 24-9535 is administratively terminated, but its claims are not dismissed — they are absorbed into the lead docket 24-6489, which controls all future proceedings.
Procedural — merits unresolvedAll three patents remain in active enforcement in the consolidated action
Consolidation does not prejudice Axsome or Antecip. The patents asserted in 24-9535 — US11986444B2, US12036191B1, and US12042473B2 — will be litigated alongside any patents from the original action. Plaintiffs gain efficiency: a single discovery track, unified scheduling, and one trial covering their full IP position against Teva’s ANDA.
Patent rights preservedTeva faces a broadened patent landscape under a single consolidated docket
Teva waived service in 24-9535 and agreed to answer by October 29, 2024 — consistent with ANDA defendants managing litigation risk cooperatively at the scheduling stage. However, consolidation means Teva must now contend with the full set of asserted patents in one proceeding, potentially increasing the complexity and cost of its invalidity and non-infringement defences.
Expanded defendant exposureMulti-patent consolidation raises the bar for Teva’s ANDA approval path
With three patents now consolidated into a single action covering dextromethorphan/bupropion ER tablets, the statutory 30-month stay mechanism under Hatch-Waxman likely applies, delaying potential generic market entry. For competitors and formulators in the CNS drug delivery space, the broadened patent assertion signals Axsome’s intent to defend Auvelity’s exclusivity comprehensively across its formulation portfolio.
Generic entry delayedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AXSOME THERAPEUTICS, INC. | Company | Specialty CNS biopharma and licensor — co-holders of DXM/bupropion ER tablet patentsSearch in Eureka ↗ |
| Co-Plaintiff | Antecip Bioventures II, LLC | Company | Search in Eureka ↗ |
| Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Global generic pharmaceutical manufacturer pursuing ANDA approval for DXM/bupropion ER tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for AXSOME THERAPEUTICS, INC.Search in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for AXSOME THERAPEUTICS, INC.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for AXSOME THERAPEUTICS, INC.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing AXSOME THERAPEUTICS, INC.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order is procedural rather than substantive — no claim has been construed, no liability determined, and no damages assessed. The order’s language (‘for all purposes, including discovery, case management, and trial’) confirms that the merged action will proceed to a full merits determination in lead docket 24-6489. The administrative termination of 24-9535 does not extinguish the asserted patents or any rights; it is a docket management mechanism. Both parties’ strategic positions remain entirely intact.
US11986444B2, US12036191B1 & US12042473B2 — DXM/Bupropion ER Tablet Formulations
The three patents in suit — US11986444B2, US12036191B1, and US12042473B2 — cover formulations and compositions related to dextromethorphan hydrobromide (DXM) and bupropion hydrochloride extended-release tablets. DXM is an NMDA receptor antagonist and sigma-1 receptor agonist; bupropion acts as a CYP2D6 inhibitor that elevates DXM plasma levels, enabling CNS activity at lower doses. The combination is the pharmacological basis of Auvelity, approved by the FDA for major depressive disorder. The application numbers (US18/488366, US18/169571, US18/354215) suggest filings across different series, consistent with a continuation or divisional prosecution strategy designed to extend IP coverage post-approval.
For generic manufacturers seeking ANDA approval referencing Auvelity, these patents represent a formidable Orange Book barrier. Each patent potentially covers distinct aspects of the formulation — composition, release profile, or method of use — meaning a paragraph IV challenge must address multiple independent claim sets simultaneously. The co-ownership structure between Axsome Therapeutics and Antecip Bioventures II indicates a licensing arrangement, and together they present a unified enforcement front. For competitors in the CNS drug delivery and combination-product space, the breadth and recency of these patents suggests sustained market exclusivity risk through the late 2030s.
Should your team run an FTO against US11986444B2, US12036191B1, and US12042473B2?
Any pharmaceutical company developing an ANDA or 505(b)(2) application referencing a DXM/bupropion extended-release combination product should treat these three patents as primary FTO targets. The consolidated enforcement action confirms Axsome and Antecip’s willingness to assert all listed patents aggressively. Formulators working on NMDA receptor antagonist combinations, sigma-1 agonist therapies, or CYP2D6-mediated dose-enhancement approaches should also assess whether their development candidate falls within the claim scope of any of these patents, even outside the ANDA context.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map their compound or formulation against the full claim set of US11986444B2, US12036191B1, and US12042473B2 in minutes. Eureka cross-references prosecution history, related family members, and cited prior art to identify design-around opportunities and freedom corridors. For teams monitoring the Axsome/Antecip portfolio, Eureka’s patent watch alerts ensure you are notified the moment additional continuation patents issue from these application families — critical intelligence for ANDA strategy and competitive product planning.
Run a freedom-to-operate analysis on US11986444B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent infringement cases in CNS drug formulation litigation
Explore related Hatch-Waxman infringement actions involving CNS combination drug formulations filed in New Jersey District Court against generic manufacturers.
What this case signals for the CNS drug delivery and ANDA IP landscape
The rapid consolidation of overlapping ANDA suits reflects a deliberate, multi-wave patent enforcement strategy increasingly common in specialty pharma.
Multi-wave ANDA filings are a core Orange Book enforcement tactic in specialty pharma
Axsome’s sequential filing — an initial action in May 2024 followed by a second suit in September 2024 covering additional patents — is consistent with listing new patents in the Orange Book as they issue. Pharma IP teams should monitor patent issuances by NDA holders post-approval, as each new listing can trigger a fresh 30-month stay window against generic challengers.
Joint consolidation requests signal early-stage litigation management, not weakness
Both parties agreeing to consolidate within 23 days suggests coordinated case management, not concession on the merits. For in-house counsel, this pattern indicates both sides are already in substantive dialogue about litigation scope and scheduling — the real strategic contest is now playing out in the lead docket under case No. 24-6489.
AXSOME v Teva — key questions answered
Consolidation merges both actions into a single proceeding under lead docket 24-6489 in the District of New Jersey. Case No. 24-9535 is administratively terminated, but its asserted patents — US11986444B2, US12036191B1, and US12042473B2 — remain in active litigation. All discovery, case management, and trial will proceed under the lead docket, with no prejudice to either party’s substantive rights.
Three U.S. patents are asserted: US11986444B2 (application no. US18/488366), US12036191B1 (application no. US18/169571), and US12042473B2 (application no. US18/354215). All three cover aspects of dextromethorphan hydrobromide and bupropion hydrochloride extended-release tablet formulations, which form the basis of Axsome’s FDA-approved product Auvelity for major depressive disorder.
The product at issue is dextromethorphan hydrobromide and bupropion hydrochloride extended-release tablets — the formulation underlying Auvelity. Teva is pursuing ANDA approval for a generic version, which triggered the Hatch-Waxman paragraph IV patent infringement litigation brought jointly by Axsome Therapeutics and Antecip Bioventures II.
The case was not resolved on the merits. It closed in 23 days because both parties jointly requested consolidation with the earlier-filed lead action, Case No. 24-6489. The court administratively terminated 24-9535 and ordered all future proceedings to be filed in the lead docket. This is a common procedural step in multi-wave ANDA litigation where additional patents are asserted after the initial suit.
Antecip Bioventures II LLC is a co-plaintiff alongside Axsome Therapeutics, suggesting it holds a co-ownership or exclusive licensing interest in one or more of the asserted patents. The joint enforcement posture is consistent with pharma IP structures where a bioventures entity holds foundational IP that is licensed to or co-developed with the NDA holder. Both entities appear as plaintiffs in both the original and consolidated actions.
PatSnap Eureka searches patents and litigation data to answer instantly.